异基因造血干细胞移植治疗骨髓增生异常综合征的研究进展

Research progress in treatment of myelodysplastic syndrome with allogeneic hematopoietic stem cell transplantation

异基因造血干细胞移植（allo-HSCT）是治疗骨髓增生异常综合征（MDS）的有效手段，亦为可能治愈MDS的唯一方法。随着造血干细胞移植（HSCT）技术的进步，越来越多的MDS患者有机会接受allo-HSCT治疗。而明确allo-HSCT治疗MDS的适应证，选择合适的移植时机、移植前治疗方案、供者及预处理方案，对MDS患者的治疗结局至关重要。因此，笔者拟就这几个方面在allo-HSCT治疗MDS中的研究进展进行综述。

Allogeneic hematopoietic stem cell transplantation （allo-HSCT） is an effective method for treatment of myelodysplastic syndrome （MDS） and is the only method that may make MDS to be curable. With the advancement of hematopoietic stem cell transplantation （HSCT）, more and more patients with MDS have the opportunity to receive allo-HSCT. Identifying the indications for allo-HSCT in treatment of MDS, selecting the appropriate timing of allo-HSCT, pre-transplant therapy, donors, stem cell sources and transplantation conditioning are critical for the treatment outcome of patients with MDS. Therefore, this article summarizes the research progress in these aspects mentioned above.